{"id":"W3025022288","doi":"10.1056/nejmoa1915745","title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":7245,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Bayer Yakuhin; Eli Lilly Japan; Chugai Pharmaceutical; Novartis Pharma; Genentech; Sirtex Medical; Ipsen; Dainippon Sumitomo Pharma; Yakult Honsha; Gilead Sciences; Servier; Advanced Accelerator Applications; Teijin Pharma; Otsuka Pharmaceutical; Eisai; BeiGene; Cisco Systems; F. Hoffmann-La Roche; Ipsen Biopharmaceuticals; Taiho Pharmaceutical; EA Pharma Co., Ltd.; Baxalta; Bayer HealthCare; Exelixis; Sanofi; Amgen; Pfizer; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atezolizumab; Bevacizumab; Hepatocellular carcinoma; Medicine; Oncology; Internal medicine; Carcinoma; Cancer; Chemotherapy; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}